首页> 中文期刊> 《中国卫生标准管理》 >替莫唑胺与放疗联合治疗恶性胶质瘤的临床分析

替莫唑胺与放疗联合治疗恶性胶质瘤的临床分析

             

摘要

目的:探究恶性胶质瘤患者采用替莫唑胺和放疗联合治疗的方法及效果。方法选取2014年8月~2015年8月收入的35例恶性胶质瘤术后患者进行治疗,随机分组,实验组20例患者给予放疗和替莫唑胺的综合治疗,对照组15例患者仅采用放疗干预,观察患者的治疗效果和安全性。结果实验组治疗总有效率为80.0%,对照组治疗总有效率为60.0%。实验组疗效具有统计学意义(P <0.05),两组患者在不良反应的发生率上没有差异(P >0.05)。结论恶性胶质瘤患者采用替莫唑胺和放疗联合治疗,效果更加显著,提高生存率,减少不良反应,改善身体舒适度和生活质量。%Objective To make an investigation on temozolomide combined with radiotherapy treatment method and its effect in treatment of malignant glioma. Methods Chose 35 patients of malignant glioma who were given postoperative treatment in hospital from August 2014 to August 2015 and separated them into two groups at random,20 patients in study group were given temozolomide combined with radiotherapy treatment,while another 15 patients in control group were given radiotherapy only,and then observed treatment effects and safety between two groups. Results Patients’treatment efficacy in study group was 80.0%,while treatment efficacy in control group was 60.0%. Thus,treatment efficacy was much higher in study group compared to that in control group(P < 0.05),but there was no differential between two groups in terms of side-effect incidence(P > 0.05). Conclusion Temozolomide combined with radiotherapy is effective in treatment of malignant glioma,it is conducive to increasing patients’survival rate,reducing side-effect incidence,promoting their physical comfort and improving patients’quality of life.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号